使用 pembrolizumab 治疗的高TMB,高MSI,耐化的前列腺癌
Satoshi Muraoka1, Hisanobu Tosuji1, Yuya Iwahashi1
1Department of Urology Wakayama Medical University Wakayama City Japan.
IJU case reports
|September 5, 2025
概括
佩姆布利祖马布对高MSI和高TMB生物标志物的晚期前列腺癌具有前景. 这项病例研究突出显示了前期治疗失败后瘤的显著反应,强调了基因组测试的必要性.
科学领域:
- 癌症学
- 基因组学
- 免疫疗法
背景情况:
- 前列腺癌的治疗,特别是晚期的癌症,往往涉及到连续的治疗.
- 微卫星不稳定性高 (MSI高) 和瘤突变负担高 (TMB高) 是免疫治疗反应的预测生物标志物.
- 在日本患有高MSI/高TMB的前列腺癌患者中,勃利祖马布的疗效数据有限.
研究的目的:
- 报告一例成功治疗日本MSI高和TMB高前列腺癌患者的病例.
- 突出基因组分析在晚期前列腺癌中的潜在益处.
- 在多次先前的全身治疗后记录pembrolizumab的反应.
主要方法:
- 一个68岁的男性患有转移前列腺癌的病例报告.
- 基因组测试显示高MSI和高TMB状态.
- 在使用雄激素受体信号抑制剂和化疗后,使用博利祖马布治疗.
主要成果:
- 患者的前列腺特异性抗原 (PSA) 水平显著降低.
- 观察到转移性病变的显著缩小.
- 患者表现出对勃利祖马布治疗的积极反应.
结论:
- 基因组测试对于识别博利祖马布等向治疗的潜在候选人至关重要,特别是在高度瘤中.
- 高MSI和高TMB的前列腺癌可能对pembrolizumab有好反应.
- 在 pembrolizumab 治疗期间,必须密切监测不良反应.
更多相关视频
06:15Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
27.5K
07:25A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
13.2K
相关概念视频
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.